101 related articles for article (PubMed ID: 35590420)
1. Ginkgolic acid and anacardic acid are reversible inhibitors of SARS-CoV-2 3-chymotrypsin-like protease.
Li D; Yan G; Zhou W; Si S; Liu X; Zhang J; Li Y; Chen Y
Cell Biosci; 2022 May; 12(1):65. PubMed ID: 35590420
[TBL] [Abstract][Full Text] [Related]
2. Discovery of naturally occurring inhibitors against SARS-CoV-2 3CL
Xiong Y; Zhu GH; Wang HN; Hu Q; Chen LL; Guan XQ; Li HL; Chen HZ; Tang H; Ge GB
Fitoterapia; 2021 Jul; 152():104909. PubMed ID: 33894315
[TBL] [Abstract][Full Text] [Related]
3. Ginkgolic acid and anacardic acid are specific covalent inhibitors of SARS-CoV-2 cysteine proteases.
Chen Z; Cui Q; Cooper L; Zhang P; Lee H; Chen Z; Wang Y; Liu X; Rong L; Du R
Cell Biosci; 2021 Feb; 11(1):45. PubMed ID: 33640032
[TBL] [Abstract][Full Text] [Related]
4. Sulforaphane is a reversible covalent inhibitor of 3-chymotrypsin-like protease of SARS-CoV-2.
Chen Z; Du R; Cooper L; Achi JG; Dong M; Ran Y; Zhang J; Zhan P; Rong L; Cui Q
J Med Virol; 2023 Mar; 95(3):e28609. PubMed ID: 36840402
[TBL] [Abstract][Full Text] [Related]
5. Development of a simple and miniaturized sandwich-like fluorescence polarization assay for rapid screening of SARS-CoV-2 main protease inhibitors.
Yan G; Li D; Lin Y; Fu Z; Qi H; Liu X; Zhang J; Si S; Chen Y
Cell Biosci; 2021 Dec; 11(1):199. PubMed ID: 34865653
[TBL] [Abstract][Full Text] [Related]
6. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
Froggatt HM; Heaton BE; Heaton NS
J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
[TBL] [Abstract][Full Text] [Related]
7. Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening.
Zhu W; Xu M; Chen CZ; Guo H; Shen M; Hu X; Shinn P; Klumpp-Thomas C; Michael SG; Zheng W
ACS Pharmacol Transl Sci; 2020 Oct; 3(5):1008-1016. PubMed ID: 33062953
[TBL] [Abstract][Full Text] [Related]
8. [Identifying SARS-CoV-2 main protease inhibitors by a novel sandwich-like fluorescence polarization screening assay].
Yan H; Yan G; Qi H; Liu Z; Liu X; Liu X; Li N; Chen Y
Sheng Wu Gong Cheng Xue Bao; 2022 Jun; 38(6):2352-2364. PubMed ID: 35786485
[TBL] [Abstract][Full Text] [Related]
9. Identification of highly effective inhibitors against SARS-CoV-2 main protease: From virtual screening to in vitro study.
Wang H; Wen J; Yang Y; Liu H; Wang S; Ding X; Zhou C; Zhang X
Front Pharmacol; 2022; 13():1036208. PubMed ID: 36467060
[No Abstract] [Full Text] [Related]
10. The SARS-CoV-2 main protease (M
Hu Q; Xiong Y; Zhu GH; Zhang YN; Zhang YW; Huang P; Ge GB
MedComm (2020); 2022 Sep; 3(3):e151. PubMed ID: 35845352
[TBL] [Abstract][Full Text] [Related]
11. Rapid peptide-based screening on the substrate specificity of severe acute respiratory syndrome (SARS) coronavirus 3C-like protease by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
Chu LH; Choy WY; Tsai SN; Rao Z; Ngai SM
Protein Sci; 2006 Apr; 15(4):699-709. PubMed ID: 16600962
[TBL] [Abstract][Full Text] [Related]
12. Potential inhibitors of coronavirus 3-chymotrypsin-like protease (3CL
Gyebi GA; Ogunro OB; Adegunloye AP; Ogunyemi OM; Afolabi SO
J Biomol Struct Dyn; 2021 Jun; 39(9):3396-3408. PubMed ID: 32367767
[TBL] [Abstract][Full Text] [Related]
13. Discovery and characterization of the covalent SARS-CoV-2 3CL
Zhang YN; Zhu GH; Liu W; Xiong Y; Hu Q; Zhuang XY; Jia GH; Zhang WD; Ge GB
Phytomedicine; 2023 Jun; 114():154796. PubMed ID: 37037086
[TBL] [Abstract][Full Text] [Related]
14. Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening.
Zhu W; Xu M; Chen CZ; Guo H; Shen M; Hu X; Shinn P; Klumpp-Thomas C; Michael SG; Zheng W
bioRxiv; 2020 Aug; ():. PubMed ID: 32803196
[TBL] [Abstract][Full Text] [Related]
15. Structural-based virtual screening and in vitro assays for small molecules inhibiting the feline coronavirus 3CL protease as a surrogate platform for coronaviruses.
Theerawatanasirikul S; Kuo CJ; Phecharat N; Chootip J; Lekcharoensuk C; Lekcharoensuk P
Antiviral Res; 2020 Oct; 182():104927. PubMed ID: 32910955
[TBL] [Abstract][Full Text] [Related]
16. Advances in research on 3C-like protease (3CL
Chen R; Gao Y; Liu H; Li H; Chen W; Ma J
RSC Med Chem; 2023 Jan; 14(1):9-21. PubMed ID: 36760740
[TBL] [Abstract][Full Text] [Related]
17. Study on the mechanism of active components of Liupao tea on 3CL
Ni WJ; Chen XX; Wei SY; Lan LL; Qiu RJ; Ling YP; Zhou DS; Wu ZM; Cao ZH; Yu CP; Zeng Y
J Food Biochem; 2021 May; 45(5):e13707. PubMed ID: 33760271
[TBL] [Abstract][Full Text] [Related]
18. Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2
Khan SA; Zia K; Ashraf S; Uddin R; Ul-Haq Z
J Biomol Struct Dyn; 2021 Apr; 39(7):2607-2616. PubMed ID: 32238094
[TBL] [Abstract][Full Text] [Related]
19. Prioritisation of Compounds for 3CL
Jukič M; Škrlj B; Tomšič G; Pleško S; Podlipnik Č; Bren U
Molecules; 2021 May; 26(10):. PubMed ID: 34070140
[TBL] [Abstract][Full Text] [Related]
20. Ligand-induced Dimerization of Middle East Respiratory Syndrome (MERS) Coronavirus nsp5 Protease (3CLpro): IMPLICATIONS FOR nsp5 REGULATION AND THE DEVELOPMENT OF ANTIVIRALS.
Tomar S; Johnston ML; St John SE; Osswald HL; Nyalapatla PR; Paul LN; Ghosh AK; Denison MR; Mesecar AD
J Biol Chem; 2015 Aug; 290(32):19403-22. PubMed ID: 26055715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
